title: Psycholeptic use in aged care homes in Tasmania, Australia.
abstract: OBJECTIVE
  Although non-drug techniques are recommended to manage sleep disturbance, anxiety and challenging behaviours associated with dementia, several studies in Australia and overseas have noted a high use of psycholeptics (anxiolytics/hypnotics and antipsychotics) in aged care homes to treat these conditions. The aim of this study was to examine the current pattern of psycholeptic use in Tasmanian aged care homes and compare this data with other Australasian research.
  
  
  METHODS
  Cross-sectional study of residents' psycholeptic use from 40 aged care homes throughout Tasmania during November 2005-January 2007.
  
  
  RESULTS
  Two thousand three hundred and eighty-nine residents were included in the study. Of the residents, over half were taking at least one psycholeptic medication regularly; over one-fifth of residents were taking antipsychotics (21%) and 43% were taking anxiolytics/hypnotics.
  
  
  CONCLUSIONS
  In comparison with other recent Australasian studies, the current level of benzodiazepine use in Tasmanian aged care homes is of major concern, at approximately three times that reported in Sydney and New Zealand. There is also substantial use of multiple psycholeptic agents. Interventions to reduce benzodiazepine use and improve psycholeptic utilization in Tasmania need to be developed urgently. The results demonstrate the value of regular auditing of prescribing to highlight problem areas in prescribing.
authors.affiliation: Unit for Medication Outcomes Research and Education (UMORE), School of Pharmacy, University of Tasmania, Hobart, 7001 Tasmania, Australia. Juanita.Westbury@utas.edu.au
authors.forename: J L
authors.initials: JL
authors.lastname: Westbury
authors.forename: S
authors.initials: S
authors.lastname: Jackson
authors.forename: G M
authors.initials: GM
authors.lastname: Peterson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D001569:Benzodiazepines / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003704:Dementia / Q000188:drug therapy; D005260:Female; D006707:Homes for the Aged / Q000706:statistics & numerical data; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D010818:Practice Patterns, Physicians' / Q000592:standards / Q000706:statistics & numerical data; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013648:Tasmania
chemical_list: D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D001569:Benzodiazepines